Attovia Therapeutics, a Phase 1 biotech developing biotherapeutics for immune-mediated diseases, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.
Attovia Therapeutics is a clinical-stage biopharmaceutical company developing biologics for immune-mediated diseases using its ATTOBODY platform, a biparatopic nanobody-based technology licensed from Alamar Biosciences. Its lead candidate, ATTO-1310, targets IL-31 and has completed Phase 1 dosing in healthy volunteers and patients with chronic pruritus and atopic dermatitis. A second candidate, ATTO-2306, is a bispecific targeting IL-13 and IL-31 for atopic dermatitis and related skin conditions, currently in IND-enabling studies with a Phase 1 trial planned for 1H27. A third candidate, ATTO-1091, is a trispecific targeting TL1A, IL-23, and integrin α4β7 for inflammatory bowel disease, also in IND-enabling studies. The company has no products on the market and no revenue from product sales to date.
The San Carlos, CA-based company was founded in 2022 and booked $1 million in revenue for the 12 months ended March 31, 2026. It plans to list on the Nasdaq under the symbol ATTO. Attovia Therapeutics filed confidentially on December 19, 2025. Morgan Stanley, Leerink Partners, Citi, RBC Capital Markets, and LifeSci Capital are the joint bookrunners on the deal.
